ASPCF Acerus Pharmaceuticals Corporation (QB)

0.21988

0.00 (0.00%)

26 Jun 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Acerus Pharmaceuticals Corporation (QB)	USOTC:ASPCF	OTCMarkets	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.21988						0.00	01:00:00

EDISON EQUITY RESEARCH - TRIMEL PHARMACEUTICALS - ENDO LAUNCHES NATESTO

23/03/2015 3:02am

InvestorsHub NewsWire

EDISON EQUITY RESEARCH - TRIMEL PHARMACEUTICALS - ENDO LAUNCHES NATESTO

US partner Endo has launched Trimel’s Natesto in the c US$2bn US testosterone replacement therapy (TRT) market. Natesto is being positioned as the first and only nasal gel for hypogonadism, and is highlighted for its lower associated risk of testosterone transference.

Trimel is a Canadian specialty pharmaceutical company. Natesto and Tefina deliver testosterone through a bio-adhesive nasal gel drug delivery technology platform, for male hypogonadism and female orgasmic disorder (FOD), respectively. Estrace is marketed for HRT in Canada.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports